Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 27395 participants.

Also called NCT01776424

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 27,395 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01776424
  • EudraCT 2012-004180-43
Main results
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial Lancet (London, England), 2018-01-20 DOI, PubMed 29132879 PubMed links an erratum for this paper. Erratum: PMID 29275871
Other papers using this trial's data
  • Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial JAMA neurology, 2020-01-01 DOI, PubMed 31524941, PMC6749537 Not in the PMC Open Access subset.
  • Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease Heart (British Cardiac Society), 2021-07 DOI, PubMed 34021038, PMC8257559 In the PMC Open Access subset under CC BY-NC.
  • Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial JAMA network open, 2022-11-01 DOI, PubMed 36409491, PMC9679876 In the PMC Open Access subset under CC BY-NC-ND.
  • Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease Cardiovascular research, 2021-02-22 DOI, PubMed 32289159 PubMed links an erratum for this paper. Erratum: PMID 33197243
  • Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial European heart journal, 2019-12-07 DOI, PubMed 31504399
  • Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial European heart journal. Cardiovascular pharmacotherapy, 2022-08-11 DOI, PubMed 34191011
  • Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial Journal of the American College of Cardiology, 2018-05-22 DOI, PubMed 29540326
  • Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin Journal of the American College of Cardiology, 2019-09-24 DOI, PubMed 31537259
  • Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent Journal of the American College of Cardiology, 2019-06-04 DOI, PubMed 31146821
  • Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease Journal of the American College of Cardiology, 2021-07-06 DOI, PubMed 34210409
  • Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial Gastroenterology, 2019-08 DOI, PubMed 31054846
  • Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches The Canadian journal of cardiology, 2024-11 DOI, PubMed 39002945
  • Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial European journal of preventive cardiology, 2020-02 DOI, PubMed 31615291
  • Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Journal of the American College of Cardiology, 2019-07-02 DOI, PubMed 31248548
  • Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial Journal of the American College of Cardiology, 2021-02-09 DOI, PubMed 33538248
  • Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial Journal of the American College of Cardiology, 2019-05-14 DOI, PubMed 31072566
  • Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease Circulation, 2019-08-13 DOI, PubMed 31163978, PMC6693980 In the PMC Open Access subset under CC BY.
  • Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial JAMA cardiology, 2021-01-01 DOI, PubMed 32997098, PMC7527938 PubMed links an erratum for this paper. Erratum: PMID 33263744 Not in the PMC Open Access subset.
  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease The New England journal of medicine, 2017-10-05 DOI, PubMed 28844192
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Lancet (London, England), 2018-01-20 DOI, PubMed 29132880
  • Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study Journal of the American College of Cardiology, 2019-01-22 DOI, PubMed 30654882
  • Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Circulation, 2020-06-09 DOI, PubMed 32223318, PMC7314494 In the PMC Open Access subset under CC BY-NC-ND.
  • Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Gastroenterology, 2019-09 DOI, PubMed 31152740
  • Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial JAMA cardiology, 2021-09-01 DOI, PubMed 34132753, PMC8209583 PubMed links an erratum for this paper. Erratum: PMID 34406323 Not in the PMC Open Access subset.
  • Stroke Outcomes in the COMPASS Trial Circulation, 2019-02-26 DOI, PubMed 30667279
  • Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease Circulation research, 2019-02 DOI, PubMed 30702997
  • The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease Circulation, 2020-07-07 DOI, PubMed 32436455 PubMed links an erratum for this paper. Erratum: PMID 32628554
  • Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial American heart journal, 2023-04 DOI, PubMed 36646196

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Ecuador, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Malaysia, Netherlands, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Sweden, Switzerland, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01776424. Randomized; quadruple masking; primary purpose prevention. Start 2013-02-28 (actual); primary completion 2017-07-21 (actual). Results posted on 2018-10-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Acronym
COMPASS
Condition
Prevention & Control
Intervention (Drug)
Rivaroxaban (Xarelto, BAY59-7939)
Intervention (Drug)
Rivaroxaban (Xarelto, BAY59-7939)
Intervention (Drug)
Aspirin
Intervention (Drug)
Aspirin placebo
Intervention (Drug)
Rivaroxaban placebo
Intervention (Drug)
Pantoprazole
Intervention (Drug)
Pantoprazole placebo
Lead sponsor
Bayer (class: industry)
Collaborator
Population Health Research Institute (class: other)
Collaborator
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01776424
Content hash
5a3152d0beaeb09b6e4181e936e59296a5736b6a3a3aa7420bee4991b782aaac